BioXcel Therapeutics Stock Forecast, Price & News

BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

Is BioXcel Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than BioXcel Therapeutics?

Wall Street analysts have given BioXcel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioXcel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for BioXcel Therapeutics.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, August, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.03) by $0.08.
View BioXcel Therapeutics' earnings history.

How has BioXcel Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BTAI stock has increased by 4.6% and is now trading at $30.85.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BTAI?

7 analysts have issued 1-year price objectives for BioXcel Therapeutics' stock. Their forecasts range from $60.00 to $141.00. On average, they expect BioXcel Therapeutics' stock price to reach $102.43 in the next twelve months. This suggests a possible upside of 232.0% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics or view top-rated stocks among Wall Street analysts.

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:

• Vimal D. Mehta, President, Chief Executive Officer & Director (LinkedIn Profile)
• Richard I. Steinhart, Chief Financial Officer & Vice President
• Frank D. Yocca, Chief Scientific Officer & Senior Vice President
• Vincent J. O'Neill, Chief Medical Officer & Senior Vice President
• William P. Kane, Chief Commercial Officer & Executive VP

Who are some of BioXcel Therapeutics' key competitors?

Some companies that are related to BioXcel Therapeutics include Galapagos (GLPG), Hypera (HYPMY), Insmed (INSM), Cytokinetics (CYTK), Prestige Consumer Healthcare (PBH), Nektar Therapeutics (NKTR), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Prothena (PRTA), PTC Therapeutics (PTCT), OPKO Health (OPK) and Sage Therapeutics (SAGE).
View all of BTAI's competitors.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $30.85.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of $862.87 million. The company earns $-82.17 million in net income (profit) each year or ($3.79) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

BioXcel Therapeutics employs 50 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

Where are BioXcel Therapeutics' headquarters?

BioXcel Therapeutics is headquartered at 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at (475) 238-6837 or via email at [email protected].